Related Experiment Video
Updated: Mar 8, 2026
05:18
Derivation of Leptomeninges Explant Cultures from Postmortem Human Brain Donors
Published on: January 21, 2017
8.7K
APOBEC3B expression in human leptomeninges and meningiomas
Mahlon D Johnson1, Jay E Reeder2, Mary O'Connell1
1Department of Pathology, Division of Neuropathology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14623, USA.
Oncology Letters
|January 20, 2017
Summary
Apolipoprotein B mRNA-editing enzyme catalytic subunit 3B (APOBEC3B) is present in meningiomas but does not drive C>T mutations. These findings suggest APOBEC3B-associated mutations are not central to meningioma pathogenesis.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The apolipoprotein B mRNA-editing enzyme (APOBEC) family is linked to cancer mutations.
- The specific role of APOBEC catalytic subunit 3B (APOBEC3B) in meningioma pathogenesis remains unclear.
Purpose of the Study:
- To investigate the expression of APOBEC3B in meningiomas and its potential role in base substitutions.
Main Methods:
- APOBEC3B expression was assessed using RT-qPCR and Western blot in meningioma tissues and cell cultures.
- Genomic DNA sequencing was performed using the Illumina Tru-Seq Cancer Panel.
- Meningioma cells were treated with cerebrospinal fluid or PDGF-BB to evaluate APOBEC3B expression changes.
Main Results:
- APOBEC3B protein was detected in fetal leptomeninges and most meningioma grades (I, II, III), with no significant difference between grades.
- No significant difference in APOBEC3B mRNA expression was observed across meningioma grades.
- Sequencing did not reveal elevated C>T mutations, characteristic of APOBEC3B activity, in meningioma DNA.
- Cerebrospinal fluid and PDGF-BB treatments did not alter APOBEC3B protein expression.
Conclusions:
- APOBEC3B is expressed in meningiomas but does not appear to drive characteristic C>T mutations.
- APOBEC3B-associated mutations may not be a primary factor in the development of meningiomas.
